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Effect of alternate.day prednisone on plasma lipids in renal transplant
recipients. While numerous groups have reported high prevalences of
plasma lipid abnormalities in their renal transplant recipients, we have
been unable to confirm this finding. We have suggested that the routine
use of alternate-day steroids (ADS) in our patients may be responsible.
To test that hypothesis, a prospective controlled trial of equal total dose
ADS versus daily steroids (DS) was conducted. Four months after
transplant and before entering the trial, transplant study patients had
significantly higher serum cholesterol (243 9 mg/dl) than either
normal controls (cholesterol 200 7 mg/dl, a = 0.01) or hemodialysis
patients (cholesterol 211 9 mg/dl, a = 0.01). They also had higher
serum triglyceride than controls (129 7 mgldl vs. 98 8 mg/dl, a =
0.01). After randomization to DS or ADS and 1 year of further followup
study, the ADS group had a significant decrease in both serum
triglyceride (139 9 to 100 7 mg/dl, P < 0.0!) and cholesterol (251
16 to 220 9 mg/dl, P < 0.05) while the DS group's serum triglyceride
and cholesterol values remained unchanged. Serum triglyceride and
cholesterol in the ADS group had decreased to values that were not
significantly different from 41 normal healthy controls. Dose spacing
per se, and not the use of a lower total dose of prednisone, appears to
result in a lower prevalence of abnormal plasma lipids after successful
renal transplantation.
Effet de Ia prednisone un jour sur deux sur les lipides plasmatiques de
transpiantés rénaux. Bien que de nombreux groupes aient reportC une
prevalence elevée d'anomalies plasmatiques lipidiques chez leurs trans-
plantCs rCnaux, nous n'avons pas pu confirmer ces résultats. Nous
avons suggére que l'administration habituelle des stéroldes unjour sur
deux chez nos malades pourrait en étre responsable. Pour tester cette
hypothese, un essai contrOlC prospectif des deux doses identiques
totales de stCroides a doses alternées (SDA), contre des stéroldes
donnés chaque jour (SD) a bté entrepris. Quatre mois aprks transplanta-
tion, et avant d'entrer dans l'essai, les transplantés de l'Ctude avaient
un cholesterol sérique significativement plus élevé (243 9 mg/dl) que
leurs contrôles normaux (cholesterol 200 7 mg/dl, a = 0,01) ou que les
malades hémodialysés (cholesterol 211 9 mg/dl, a = 0,01). Its avaient
également des triglycerides seriques significativement plus ClevCs que
les contrôles (129 7 mg/d!, contre 98 8 mg/dl, a 0,01). Après
tirage au sort entre ADS ou DS et après un an de suivi, le groupe ADS
avait une diminution significative des triglycerides sériques (139 9 a
100 7 mgldl, P < 0,01) et du cholesterol (251 16 a 220 9 mg/dl, P
<0,05), tandis que dans le groupe DS, les triglycerides et le cholesterol
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sériques étaient inchanges. Les triglycerides et Ic cholesterol sCrique du
groupe ADS étaient revenus a des valeurs non significativement differ-
entes de 41 sujets normaux contrOles. Ainsi, c'est I'espacement des
doses en soi, et non l'emploi d'une plus faible dose totale de prednisone
qui semble diminuer Ia prevalence d'anomalies des lipides plasmatiques
après transplantation réussie.
transplantation [1, 21. Both hypercholesterolemia [3, 4] and
hypertriglyceridemia [5, 6] have been considered risk factors
for death from atherosclerotic vascular disease. More recently
low serum concentrations of high density lipoprotein cholester-
ol (HDL-cholesterol) have also been associated with a higher
risk of cardiovascular death [7, 81.
Young renal transplant recipients (age, 15 to 34 years) have
five deaths per year per thousand patients at risk from myocar-
dial infarction, cardiac arrest, and cerebral vascular accidents
whereas older transplant recipients (age, 35 to 54 years) have
18.5 deaths per year per thousand patients at risk from these
causes [9]. Thus, after infection, atherosclerotic disease is the
most important cause of death for transplant patients [9]. Ibels
et al [10] point out that the risk of myocardial infarction for
transplant patients is 25 times greater than that in the general
population and that of cerebral vascular accident 300 times
greater. Since Ghosh et al [11] first noted a high prevalence of
hyperlipidemia among transplant recipients, there have been
frequent suggestions [1, 2, 12—14] that this abnormality may
contribute to the high prevalence of atherosclerotic deaths seen
in this population.
Ghosh's initial observation has been confirmed repeatedly [1,
2, 12—161. On the other hand, we have reported a much lower
prevalence of hyperlipidemia in our transplant clinic population
[17, 181. Our patients differed from the other reports in that all
were on maintenance alternate-day prednisone. We speculated
that alternate-day steroids (ADS) might be responsible for our
findings. However, Ibels, Aifrey, and Weil [19] suggested that
our findings were due to lower total prednisone dose and not
dose spacing per se.
We now report results of a prospective controlled study on
the effects of predriisone dose spacing on plasma lipids after
renal transplantation. Plasma lipids improved in the ADS study
group but not in the equivalent total dose daily steroid (DS)
study group.
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Table 1. Body weight and serum creatinine
Methods
Over a 2.5-year period, chronic renal failure patients who had
received a renal transplant, had a serum creatinine 2.0 mg/dl
4 months after the transplant operation, and who were less than
50 years of age and did not have insulin-dependent diabetes
mellitus as the cause of their renal failure, were asked to
participate in the plasma lipid study. All study patients gave
written informed consent.
At the time of entry into the study all patienis were on 30 mg
of prednisone daily (single A.M. dose) and had had their
transplanted kidney for 4 months. They had received 100 mg of
prednisone daily on the day of transplant and had been tapered
to 30 mg of prednisone as previously described [201. The
patients then were assigned randomly to either a DS or an ADS
group. The DS group decreased prednisone dose 2.5 mg every
week until they reached a dose of 15 mg/day (single A.M. dose).
The ADS group decreased prednisone 2.5 mg every fourth day
until they reached a dose of 30 mg of prednisone every other
day. Both regimens required about 6 weeks to achieve mainte-
nance dosages.
Initially, 15 patients were in the DS group and 17 in the ADS
group. One patient in the DS group lost graft function during the
next year of followup and returned to dialysis. In the ADS
group, two patients lost graft function and returned to dialysis
and one other patient developed chronic rejection with a serum
creatinine concentration of 4.6 mgldl after 12 months' followup
and was dropped from the study. All other patients maintained
excellent graft function (serum creatinine 2.0 mg/dl) and
remained in the study. Thus, 14 DS and 14 ADS patients
completed 1 year of followup.
In the DS group there were seven women and eight men with
a mean age of 33 2 years (mean sEM); six had received
grafts from living related donors and eight from cadavers. In the
ADS group there were nine women and five men with a mean
age of 30 3 years; eight had received grafts from living related
donors and six from cadavers.
Study patients had serum samples obtained for triglycerides,
cholesterol and HDL-cholesterol concentrations at entry into
the study and 1 year later. Serum lipids were also determined in
eight of the DS group and nine of the ADS group prior to
transplantation while they were on hemodialysis. None of the
study patients were on diuretics while on hemodialysis and
because diuretics have been incriminated as potential causes of
hypertriglyceridemia after transplantation [211, diuretic medica-
tions were recorded at entry into study and 1 year later. Body
weights were noted at entry into the study and 1 year later.
For normal controls, 41 hospitalized candidates for kidney
donation had serum cholesterol, triglyceride, and HDL-choles-
terol concentrations determined. All had normal renal function,
were less than 50 years of age, and had a normal physical
examination. They live in the same geographic area and are of
similar socioeconomic status to the transplant study patients.
There were 22 women and 19 men with a mean age of 33 1.3
years (range, 18 to 48 years). For hemodialysis controls, 62
patients under the age of 50 and treated by chronic hemodialysis
had serum cholesterol, triglyceride, and HDL-cholesterol con-
centrations determined. There were 15 women and 47 men with
a mean age of 31 1.4 years (range, 14 to 49 years).
In all cases, serum lipoprotein determinations were obtained
after a 16-hr fast. The manual method of Levy [22] was used for
triglyceride analysis. Triolein standards, control sera, and pa-
tient sera were analyzed together in duplicate. Reconstituted
Lipitrol (Dade Pharmaceuticals, Hallandale, Florida) served as
control serum; the mean value of Lipitrol was 184 mg/dl versus
the stated value of 186 mg/dl, and the coefficient of variation
was 1.7%. Total serum cholesterol was determined according
to the method of Franley and Amador [231, and in all instances
standards and patients and control sera were used for the
cholesterol analyses. The mean value obtained for the Lipitrol
was 344 mg/dl versus the stated value of 346 mg/dl with a
coefficient variation of 1.8%. Lipoprotein electrophoresis
was carried out on paper in human albumin buffer according to
the method of Lees and Hatch [241. Blood was obtained in
vacutainer tubes containing disodium EDTA, placed on ice, and
centrifuged. High-density lipoprotein cholesterol was deter-
mined by the manganese-heparin precipitation method [251.
Paired and unpaired Student's t test were used to compare
results as appropriated. When more than two groups were
compared, the Kruskal-Wallis test for one-way analysis of
variance was performed; individual mean groups were com-
pared using Dunn's procedure for multiple comparisons [26].
The value a = 0.05 was considered significant.
Results
As can be seen in Table 1, both groups had significant body
weight gains during the first 4 months after transplantation.
Mean body weight continued to increase during the year of
study on ADS and DS with each group having a similar 5%
increase in body weight during the study, Serum creatinines
remained stable in all study patients.
Plasma lipids of our controls, chronic hemodialysis patients,
and our composite group of 28 study patients 4 months after
transplantation are shown in Table 2. As expected the hemodi-
On dialysis
4 months
after TX
Body weight, lbs Serum creatinine, mgldl
ADS group 137 8 154 9* (112%) 162 9* (1 5%)(N= 14)
DS group 136 7 143 9* (15%) 150 10* (15%)(N = 14)
16 months
after TX
4 months
after TX
1.6 0.1
1.4 0.1
Symbols and abbreviations are: ( ), % increase in mean body weight over previous value; *, P< 0.01 compared to dialysis body weight; ADS, al-
ternate-day steroids; DS, daily steroids; TX, kidney transplant.
16 months
after TX
1.5 0.1
1.3 0.1
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Table 2. Plasma lipids for controls, hemodialysis patients and study patients four months after transplantation
0Serum triglyceride
mgldl
Serum cholesterol
mg/dl
HDL-cholesterol, mgldl
Males Females
Controls (C)
(N = 41)
98 8a
(9flb
200 7
(197)
39 3
(35)
45 3
(47)
Hemodialysis (H) patients
(N = 62)
154 11
(136)
211 9
(195)
37 1
(37)
42 3
(42)
Transplant (TX) study patients
(4 months after transplant)
(N = 28)
129 7
(128.5)
243 9
(246)
54 4
(55)
58 5
(56.5)
P values TX vs. C (a = 0.01)
TX vs. H (a = NS)
C vs. H (a = 0.01)
TX vs. C (a = 0.01)
TX vs. H (a = 0.01)
C vs. H (a = NS)
TX vs. C (a = 0.05)
TX vs. H (a 0.01)
C vs. H (a = NS)
TX vs. C (a = NS)
TX vs. H (a = NS)
C vs. H (a = NS)
a Mean value SEM.
Median value.
alysis patients had significantly higher mean serum triglyceride
concentration than controls; 154 11 mg/dl versus 98 8 mg/dl
(a = 0.01). The transplanted patients had a significantly higher
mean serum cholesterol concentration than either the controls
or hemodialysis patients. They also have a significantly higher
mean serum triglyceride concentration than the controls but not
higher than the hemodialysis patients. The transplant male
patients have a significantly higher HDL-cholesterol concentra-
tion than the hemodialysis patients or controls.
This same pattern of differences is seen in the 17 transplant
patients who had sequential plasma lipids measured when on
hemodialysis and at the entry into the study 4 months after
transplantation (Fig. 1).
Thus, at the time of randomization (4 months after transplan-
tation) our study patients had a significant gain in body weight,
a significant increase in serum cholesterol and HDL-cholesterol
concentrations, and a trend toward a decrease in serum triglyc-
eride concentration. These plasma lipid differences are noted
either in comparison to a large group of hemodialysis patients
(Table 2) and/or to their own values on hemodialysis (Fig. 1).
One year after randomization the ADS group had a mean
decrease of 38 mg/dl in serum triglyceride concentration (P <
0.01) while the DS group had a decrease of 1 mg/dl (P = NS)
(Fig. 2). Mean serum triglyceride concentration for the ADS
group was now similar to the control group (100 7 versus 98
8, P = NS) and significantly lower than the hemodialysis group
(P < 0.01).
One year after randomization the ADS group had a mean
decrease of 31 mg/dl in serum cholesterol concentration (P <
0.05) while the DS group had a slight increase of 3 mg/dl in mean
serum cholesterol (P = NS) (Fig. 2). The ADS group was now
not significantly different from the controls (220 9 mg/dl
versus 200 7 mg/dl, P = NS) while the DS group remained
significantly higher (239 16 mg/dl versus 200 7 mg/dl, P <
0.02) than controls.
One year after randomization HDL-cholesterol remained in
the normal range for both the ADS and DS groups and neither
group changed significantly from their 4-month value. As
expected, HDL-cholesterol was higher for females than males
in all groups studied.
The above results are mean serum values for the groups. If
one considers serum triglyceride above 150 mg/dl and serum
cholesterol above 250 mg/dl to be abnormal, eight (57%) of the
ADS study patients entered the study with abnormal values and
only four (28.5%) had abnormal values for serum triglyceride
and/or cholesterol after the years' exposure to ADS. This 28.5%
prevalence is similar to our previously reported prevalence for
our entire transplant clinic population who were all on ADS
[171. On the other hand, eight (57%) DS study patients entered
the study with abnormal serum triglyceride and/or cholesterol
values and eight (57%) finished the study with abnormal values.
At4 months after transplantation, 12 of the 14 patients in both
the DS and ADS groups were on diuretic therapy. When serum
samples were obtained 1 year later, six of the ADS patients
were receiving diuretics, compared to seven of the DS group.
At that time two ADS patients were taking antihypertensive
medications other than diuretics, and five DS patients required
antihypertensive medications other than diuretics. Serum tri-
glyceride was not significantly different between patients on
diuretics versus those not on diuretics within either group. DS
patients on diuretics had a mean triglyceride of 126 25 mg/dl
versus 110 18 mg/dl for those not on diuretics; ADS patients
had a mean serum triglyceride of 100 17 mg/dl for those on
diuretics versus 99 7 for those not on diuretics.
Discussion
Our results confirm the observation that hemodialysis pa-
tients have plasma lipid abnormalities mainly characterized by
hypertriglyceridemia [1, 271 while renal transplant patients have
plasma lipid abnormalities mainly characterized by hypercho-
lesterolemia [1, 121. Moreover, the sequential measurements of
lipids in the same patients, while on dialysis, and then 4 months
after transplant demonstrates that the dominant plasma lipid
abnormality changes in patients, that is, initially after transplan-
tation, serum cholesterol increases significantly while serum
triglyceride begins to decrease. After conversion to ADS we
have demonstrated a significant decrease in both cholesterol
and triglyceride to values not significantly different from con-
trols. At an equal total dose, the DS group did not experience
these decreases.
250
200
150
100
50
16 Months after TX
Triglyceride Cholesterol Triglyceride Cholesterol
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200 —
100 -
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Fig. 1. Sequential measurements of plasma lipids in the same patients
while on dialysis and 4 months after transplantation with the same
changes noted when different groups are compared (Table 2). For these
17 patients serum cholesterol increased from 177 7 mgldl to 241 10
mgldl (P < 0.01); HDL-cholesterol increased from 34 3 mgldl to 47
5 mgldl (P < 0.01). Serum triglyceride decreased from 157 12 mg/dl to
137 12 mgldl (P = NS). TX represents renal transplantation.
Hypertriglyceridemia in hemodialysis patients is believed to
be due to a defect in triglyceride removal and/or increased
insulin resistance. Because both of these mechanisms are
attributed to uremia, it would seem logical that successful
transplantation should reverse the problem. However, since
Ghosh et al's early report [11] of high prevalence of lipoprotein
abnormalities in transplanted patients, many other groups have
observed similar prevalences [1, 2, 13—161. It, therefore,
seemed possible that post-transplant drug therapy (corticoste-
roids) was a factor and, indeed, in our transplant population
routinely maintained on ADS, plasma lipids were nearly normal
[171. Our current prospective control study further supports the
hypothesis that DS is a major factor in perpetuating postrenal
transplant lipid abnormalities. Reaven, Kolterman, and Reaven
[28] demonstrated that hypercholesterolemia could be produced
in rats with corticosteroids. We have demonstrated that rats
given corticosteroids in an ADS regimen have improved lipo-
protein patterns compared to rats given identical dose steroids
in a DS regimen [291. The present report suggests that this is
also true in man.
Cattran et al [121 have reported that six of seven renal
transplant patients had decreases in serum triglyceride produc-
tion rates after conversion from DS to equal dose ADS. This
data support and suggest a mechanism for our current findings.
On the other hand, neither Ibels, Alfrey, and Weil [191 nor
Ponticelli et al [13] were able to demonstrate statistically
significant differences in plasma lipids of patients treated with
DS compared to others treated with ADS. Ibels, Aifrey, and
Weil compared eight pediatric transplant patients on ADS who
had significantly longer followup and were on significantly less
Fig. 2. DS and ADS study groups. One year after entry into DS and
ADS study groups, the 14 DS patient's serum triglyceride and choles-
terol concentrations had not changed significantly while the 14 ADS
study patients had a decrease in both serum triglyceride concentration,
139 9 mg/dl to 100 7 mg/dl (P < 0.01, two asterisks) and serum
cholesterol concentration 251 16 mg/dl to 220 9 mg/dl (P < 0.05,
one asterisk). TX represents renal transplantation.
prednisone to 11 DS pediatric transplant patients. The reason
ADS was employed in the eight patients was not reported. The
ADS group had lower mean serum triglyceride (136 29 mg/dl
versus 186 24 mg/dI) and serum cholesterol (246 15 mg/dl
versus 251 12 mg/dl) than the DS group, but the differences
did not achieve statistical significance. Ponticelli et al also
noted lower mean serum triglyceride (180 85 mg/dl versus 208
121 mg/dl) and serum cholesterol (219 55 mg/dl versus 234
52 mg/dl) for an ADS group of transplant patients compared
to a DS group but again these differences did not achieve
statistical significance. In the report of Ponticelli et al the ADS
group had a shorter followup than the DS group and were on a
slightly higher mean prednisone dose. Again, the reason for
selection of ADS was not reported. Our study differs from those
studies in that it was prospective, randomized, and had a DS
control group with the same steroid exposure and followup
time. Moreover, sequential plasma lipids were obtained which
revealed significant decreases in both triglyceride and choles-
terol for the ADS group.
Factors other than corticosteroids that have been suggested
to be important in transplant patient hyperlipidemia include diet
[13, 301 and diuretic therapy [21]. In our study no dietary
manipulations were carried out and both DS and ADS groups
gained the same percentage of weight after randomization. Both
groups also had similar exposure to diuretic therapy. It is
interesting to note that in the ADS group following transplanta-
tion serum triglyceride actually fell despite the administration of
diuretics and marked body weight gains.
HDL-cholesterol depression in transplant patients has been
reported by Bagdade and Albers [31]. We [181 and other groups
150
E
Serumeride
Study patients while
on hemodialysis(N= 17)
Study patients
4 months after TX
IN= 17)
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[1, 14, 21, 32] have not observed this phenomenon. In this study
HDL-cholesterol returned to normal values by 4 months after
transplantation.
Recently, Evans and Ghosh have reinvestigated the surviving
patients in their initial report of post-transplant hyperlipidemia
and noted that their lipid patterns have returned to normal 6
years later [33]. Thomas and Lee have also reported normal
lipid patterns in transplant patients 10 years after their trans-
plant [34]. Gokal et al [321 suggest the reason many transplant
groups report high prevalences of lipoprotein abnormalities
may be related to the "cross-sectional" nature of the studies.
They suggest that sequential measurements of serum lipids
demonstrate a decrease in abnormal values with time and
decreasing prednisone dosage. Our current study suggests that
ADS therapy results in a decrease to normal values by 1 year.
While ADS regimens appear to produce less hypertension
[35, 361, fewer infections [37, 38], less obesity [39, 40], and in
this report improved serum lipoprotein levels, many groups
continue to employ DS for routine post-transplant immunosup-
pression in adults because of fear of graft rejection. We have
recently reported data [411 that suggest that equal doses of
steroids given in an ADS regimen are less "immunosuppres-
sive" than when given in a DS regimen and, thus we hypothe-
size, may be associated with fewer infections but more rejec-
tions, although renal function in that study was not altered by
ADS. However, we are aware of only two controlled trials of
the influence of ADS versus DS on graft survival and both
revealed no effect [42, 43]. Moreover, the recent EDTA pooled
data suggest no difference in graft loss in children on ADS
versus DS [44]. In the current study three of the initial 17
patients in the ADS group and one of the initial 15 patients in
the DS group lost function of their grafts during the years'
followup (x2 = 0.16, P = NS). While this difference in graft
survival is most likely due to chance, it is the first controlled
study in which ADS graft survival was not greater or equal to
DS graft survival.
The results of this study suggest that ADS is associated with a
normalization of plasma lipids in the 4- to 16-month period after
successful renal transplantation. To the extent that post-trans-
plant hypercholesterolemia and hypertriglyceridemia contrib-
ute to post-transplant arteriosclerotic vascular disease, the
prudent use of ADS should be beneficial in that regard.
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